Predictive Human Toxicity and ADME/Tox Studies
These studies revealed two main points: first, that toxicity in animals may be likely to also be present in humans, though this cannot be considered particularly consistent or reliable, due to considerable variability and lack of any clear pattern in types of toxic effects; and secondly, perhaps more crucially, that the absence of toxicity in animals provides essentially no insight into the likelihood of toxicity or absence of toxicity in humans. Pharmacokinetics involves the study of absorption, distribution, metabolism, excretion and toxicity of xenobiotics (ADME-Tox). In this sense, the ADME-Tox profile of a bioactive compound can impact its efficacy and safety. Moreover, efficacy and safety were considered some of the major causes of clinical failures in the development of new chemical entities. In this context, machine learning (ML) techniques have been often used in ADME-Tox studies due to the existence of compounds with known pharmacokinetic properties available for generating predictive models.
- Corrosive agents
- Non-volatile organic substances
- Anions and non-metals
Related Conference of Predictive Human Toxicity and ADME/Tox Studies
20th World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
18th International Conference on Human Genomics and Genomic Medicine
16th International Conference on Human Genetics and Genetic Diseases
19th International Conference on Genomics & Pharmacogenomics
Predictive Human Toxicity and ADME/Tox Studies Conference Speakers
Recommended Sessions
- Adverse Outcome Pathways
- Biomarkers in Toxicogenomics
- Cardiovascular Toxicology
- Concept of Toxicogenomics
- Drug monitoring
- Genetic Toxicology
- Genomic Approaches to Predictive Toxicology
- Predictive Human Toxicity and ADME/Tox Studies
- Reproductive and Developmental Toxicology
- Technologies in Toxicogenomics
- Toxicogenomics
- Toxicology study in Haemostasis
- Toxicopathology
Related Journals
Are you interested in
- Achieving efficient delivery and editing - CRISPR 2025 (Italy)
- Bioinformatics - HUMAN GENOME 2025 (France)
- Cancer and stem cells - CRISPR 2025 (Italy)
- Cancer Genomics - HUMAN GENOME 2025 (France)
- Cognitive Computing - HUMAN GENOME 2025 (France)
- Computational Biology - HUMAN GENOME 2025 (France)
- CRISPR technologies and society - CRISPR 2025 (Italy)
- CRISPR technologies beyond genome editing and gene regulation - CRISPR 2025 (Italy)
- Drug Detection & Development in Bioinformatics - HUMAN GENOME 2025 (France)
- Emergency Medicine - HUMAN GENOME 2025 (France)
- Epigenetics Biomarkers - HUMAN GENOME 2025 (France)
- Genetically Modified Organisms - HUMAN GENOME 2025 (France)
- Genome editing and gene regulation in human health - CRISPR 2025 (Italy)
- Genome editing and gene regulation in industrial bacterial biotechnology - CRISPR 2025 (Italy)
- Genome editing and gene regulation in industrial eukaryotic biotechnology - CRISPR 2025 (Italy)
- Genome Editing Methods and Novel Tools - CRISPR 2025 (Italy)
- Genome Mapping - HUMAN GENOME 2025 (France)
- Genomic Approach to Drug Discovery - HUMAN GENOME 2025 (France)
- Genomic Information in Medicine - HUMAN GENOME 2025 (France)
- Genomic Vaccination - HUMAN GENOME 2025 (France)
- Genomics - HUMAN GENOME 2025 (France)
- Horizons of CRISPR biology - CRISPR 2025 (Italy)
- Human Gene Therapy - HUMAN GENOME 2025 (France)
- Human Genetics - HUMAN GENOME 2025 (France)
- Infectious Diseases - HUMAN GENOME 2025 (France)
- Medicine Genomics - HUMAN GENOME 2025 (France)
- Personalized Medicine - HUMAN GENOME 2025 (France)
- Pharma Genomics & Pharma Informatics - HUMAN GENOME 2025 (France)
- Plant and Animal Biotechnology - CRISPR 2025 (Italy)
- Preimplantation Genetic Diagnosis - HUMAN GENOME 2025 (France)
- Structural Biology and Bioinformatics - CRISPR 2025 (Italy)
- Therapeutic Genome Editing - CRISPR 2025 (Italy)